The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hemodynamic monitoring market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Hemodynamic monitoring refers to the process of measuring the blood flow and pressure exerted in the heart, veins and arteries. It enables the assessment and optimization of hemodynamic parameters and oxygen delivery, which helps in diagnosing and treating various cardiopulmonary conditions and improving outcomes in critically ill patients. Over the years, hemodynamic monitoring has evolved from basic tracking of cardiac output (CO) to advanced devices that provide information about a wide array of variables, like blood pressure, blood volume and fluid balance.
Over the years, there has been a rise in the number of people suffering from cardiac dysfunction, which results in hemodynamic instability, thus ultimately leading to organ failure. Consequently, the demand for hemodynamic monitoring has significantly increased across the globe. In line with this, the introduction of more innovative, uncalibrated and non-invasive CO measurements obtained through the analysis of a non-invasive arterial pressure waveform is also contributing to the market growth. Furthermore, hemodynamic monitoring is being increasingly used across the healthcare sector to improve patient outcome and combat tissue hypoxia, shock and multiorgan failure in critically ill patients. Extensive research and development (R&D) activities act as another major growth-inducing factor. Manufacturers are undertaking initiatives for the development of simpler minimally- and non-invasive hemodynamic monitoring systems at affordable prices, which will offer more precise results. Other factors, rising healthcare expenditure by both government and private sectors and technological advancements, are further expected to create a positive outlook for the market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemodynamic monitoring market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, monitoring and end-user.
Breakup by Product:
Breakup by Monitoring:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Edwards Lifesciences Corporation, Lidco Group PLC, Deltex Medical Group PLC, Pulsion Medical Systems SE, GE Healthcare, Osypka Medical GmbH, Tensys Medical, Teleflex Incorporated, ICU Medical Inc., Argon Medical, Schwarzer Cardiotek GmbH, etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Monitoring, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Edwards Lifesciences Corporation, Lidco Group PLC, Deltex Medical Group PLC, Pulsion Medical Systems SE, GE Healthcare, Osypka Medical GmbH, Tensys Medical, Teleflex Incorporated, ICU Medical Inc., Argon Medical and Schwarzer Cardiotek GmbH|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at